{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:13Z","timestamp":1785860293239,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the European Union\u2019s Horizon 2020 research and innovation program under the Marie Sk\u0142odowska-Curie grant agreement","award":["No. 847639"],"award-info":[{"award-number":["No. 847639"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cerium oxide nanoparticles (CeO NPs) are showing neuroprotective effects in various experimental models of neurodegeneration. Doping of nanoparticles with magnetic resonance imaging (MRI) contrast agents (e.g., gadolinium) could enable simultaneous diagnosis and treatment of neurodegenerative diseases, a technology called theranostics that is used primarily in oncology but can also be successfully applied in the diagnosis and treatment of neurodegenerative diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we doped polyacrylic acid conjugated cerium oxide nanoparticles with gadolinium (Gd-CeO) to create a theranostic agent with MRI capabilities and neuroprotective properties. These nanoparticles were evaluated for their physicochemical characteristics, magnetic resonance imaging potential, biosafety profile, cellular uptake, and neuroprotective effects compared to CeO nanoparticles (CeO) in a human neuronal model of Parkinson\u2019s disease employing undifferentiated and retinoic acid-differentiated SH-SY5Y cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The synthesized Gd-CeO nanoparticles showed good stability, concentration-dependent T\n                      <jats:sub>1<\/jats:sub>\n                      and T\n                      <jats:sub>2<\/jats:sub>\n                      contrast features, and were not cytotoxic. The Gd-CeO nanoparticles were rapidly taken by cells and maintained neuroprotective potency against hydrogen peroxide (H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      )- and 6-hydroxydopamine (6-OHDA)-induced cell damage to a similar extent as did CeO nanoparticles without Gd doping. Moreover, we demonstrated a protective effect of Gd-CeO and CeO nanoparticles on mitochondrial membrane potential, DNA fragmentation, and the number of necrotic cells in both models of cell injury, whereas at the level of caspase-3 activity, we showed an inhibitory effect of the studied NPs only in the 6-OHDA model. Finally, the protection mediated by Gd-CeO and CeO nanoparticles against H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      was confirmed in mouse primary cortical neurons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Since the developed Gd-CeO nanoparticles showed promising contrast features, as well as maintaining biosafety and neuroprotective properties similar to those of nanoparticles without Gd doping, they could be further investigated as a potential theranostic probe for neurodegenerative diseases, including Parkinson\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00863-5","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:14:56Z","timestamp":1778307296000},"page":"1119-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of gadolinium doping on physicochemical properties and neuroprotective activity of polyacrylic acid conjugated cerium oxide nanoparticles \u2013 in vitro study of potential theranostics for neurodegenerative diseases"],"prefix":"10.1007","volume":"78","author":[{"given":"Rugmani","family":"Meenambal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Kruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Warszy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"\u0141opuszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142aw P.","family":"W\u0119glarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Stan-G\u0142owi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wojewoda-Budka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Jasi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"M\u0105sior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-4489","authenticated-orcid":false,"given":"Danuta","family":"Jantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","volume":"138","author":"SM Dadfar","year":"2019","unstructured":"Dadfar SM, Roemhild K, Drude N, von Stillfried S, Kn\u00fcchel R, Kiessling F, et al. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302\u201325. https:\/\/doi.org\/10.1016\/j.addr.2019.01.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbpa.2015.05.02","volume":"28","author":"R Kojima","year":"2015","unstructured":"Kojima R, Aubel D, Fussenegger M. Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells. Curr Opin Chem Biol. 2015;28:29\u201338. https:\/\/doi.org\/10.1016\/j.cbpa.2015.05.02.","journal-title":"Curr Opin Chem Biol"},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"122899","DOI":"10.1016\/j.lfs.2024.122899","volume":"352","author":"AN Al-Thani","year":"2024","unstructured":"Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. Life Sci. 2024;352:122899. https:\/\/doi.org\/10.1016\/j.lfs.2024.122899.","journal-title":"Life Sci"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.bioactmat.2022.11.013","volume":"23","author":"J Li","year":"2022","unstructured":"Li J, Wang S, Fontana F, Tapeinos C, Shahbazi MA, Han H, et al. Nanoparticles-based phototherapy systems for cancer treatment: Current status and clinical potential. Bioactive Mater. 2022;23:471\u2013507. https:\/\/doi.org\/10.1016\/j.bioactmat.2022.11.013.","journal-title":"Bioactive Mater"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","volume":"7","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020;7:193. https:\/\/doi.org\/10.3389\/fmolb.2020.00193.","journal-title":"Front Mol Biosci"},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.7150\/thno.38147","volume":"10","author":"M Zhao","year":"2020","unstructured":"Zhao M, van Straten D, Broekman MLD, Pr\u00e9at V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10:1355\u201372. https:\/\/doi.org\/10.7150\/thno.38147.","journal-title":"Theranostics"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00415-020-10291-x","volume":"268","author":"J Baskin","year":"2021","unstructured":"Baskin J, Jeon JE, Lewis SJG. Nanoparticles for drug delivery in Parkinson\u2019s disease. J Neurol. 2021;268:1981\u201394. https:\/\/doi.org\/10.1007\/s00415-020-10291-x.","journal-title":"J Neurol"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"9690","DOI":"10.3390\/ijms25179690","volume":"25","author":"A Dey","year":"2024","unstructured":"Dey A, Ghosh S, Rajendran RL, Bhuniya T, Das P, Bhattacharjee B, et al. Alzheimer\u2019s Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions. Int J Mol Sci. 2024;25:9690. https:\/\/doi.org\/10.3390\/ijms25179690.","journal-title":"Int J Mol Sci"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fnins.2020.00305","volume":"14","author":"A Kumar","year":"2020","unstructured":"Kumar A, Chaudhary RK, Singh R, Singh SP, Wang SY, Hoe ZY, et al. Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases. Front Neurosci. 2020;14:305. https:\/\/doi.org\/10.3389\/fnins.2020.00305.","journal-title":"Front Neurosci"},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.3390\/molecules27113561","volume":"27","author":"S Mehan","year":"2022","unstructured":"Mehan S, Arora N, Bhalla S, Khan A, U Rehman M, Alghamdi BS, et al. Involvement of Phytochemical-Encapsulated Nanoparticles\u2019 Interaction with Cellular Signalling in the Amelioration of Benign and Malignant Brain Tumours. Molecules. 2022;27:3561. https:\/\/doi.org\/10.3390\/molecules27113561.","journal-title":"Molecules"},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"16099","DOI":"10.1038\/s41598-019-52622-7","volume":"9","author":"HA Miller","year":"2019","unstructured":"Miller HA, Magsam AW, Tarudji AW, Romanova S, Weber L, Gee CC, et al. Evaluating differential nanoparticle accumulation and retention kinetics in a mouse model of traumatic brain injury via Ktrans mapping with MRI. Sci Rep. 2019;9:16099. https:\/\/doi.org\/10.1038\/s41598-019-52622-7.","journal-title":"Sci Rep"},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"707441","DOI":"10.3389\/fcell.2021.707441","volume":"9","author":"FL Zoey","year":"2021","unstructured":"Zoey FL, Palanivel M, Padmanabhan P, Guly\u00e1s B. Parkinson\u2019s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation. Front Cell Dev Biol. 2021;9:707441. https:\/\/doi.org\/10.3389\/fcell.2021.707441.","journal-title":"Front Cell Dev Biol"},{"key":"863_CR14","doi-asserted-by":"publisher","unstructured":"Ali A, A Emad N, Sultana N, Waheed A, Aqil M, Sultana Y, et al. Navigating into the Paradigm of Nose-to-brain delivery of nanotherapeutics and their repurposing as nanotheranostics for neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2024 Oct 11. https:\/\/doi.org\/10.2174\/0118715273319597240927044906.","DOI":"10.2174\/0118715273319597240927044906"},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"fcaa193","DOI":"10.1093\/braincomms\/fcaa193","volume":"2","author":"J Debatisse","year":"2020","unstructured":"Debatisse J, Eker OF, Wateau O, Cho TH, Wiart M, Ramonet D, et al. PET-MRI nanoparticles imaging of blood-brain barrier damage and modulation after stroke reperfusion. Brain Commun. 2020;2:fcaa193. https:\/\/doi.org\/10.1093\/braincomms\/fcaa193.","journal-title":"Brain Commun"},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12951-021-01067-0","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Li S, Cui Y, Liang X, Shan J, et al. Functionalized nanoparticles with monocyte membranes and rapamycin achieve synergistic chemoimmunotherapy for reperfusion-induced injury in ischemic stroke. J Nanobiotechnol. 2021;19:331. https:\/\/doi.org\/10.1186\/s12951-021-01067-0.","journal-title":"J Nanobiotechnol"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1089\/neu.2016.4644","volume":"37","author":"ZS Bailey","year":"2020","unstructured":"Bailey ZS, Nilson E, Bates JA, Oyalowo A, Hockey KS, Sajja VSSS, et al. Cerium Oxide Nanoparticles Improve Outcome after In Vitro and In Vivo Mild Traumatic Brain Injury. J Neurotrauma. 2020;37:1452\u201362. https:\/\/doi.org\/10.1089\/neu.2016.4644.","journal-title":"J Neurotrauma"},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"123379","DOI":"10.1016\/j.biomaterials.2025.123379","volume":"322","author":"J Nan","year":"2025","unstructured":"Nan J, Xia C, Zhang J, Xie Y, Shi S, Yang W, et al. Gadolinium-ceria hybrid system enables synergistic alleviation of oxidative stress and metabolic thrombo-inflammation for efficient ischemic stroke treatment. Biomaterials. 2025;322:123379. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123379.","journal-title":"Biomaterials"},{"key":"863_CR19","doi-asserted-by":"publisher","unstructured":"Rzigalinski BA, Carfagna CS, Ehrich M. Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9. https:\/\/doi.org\/10.1002\/wnan.1444.","DOI":"10.1002\/wnan.1444"},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1007\/s11033-020-05354-1","volume":"47","author":"E Singh","year":"2020","unstructured":"Singh E, Devasahayam G. Neurodegeneration by oxidative stress: a review on prospective use of small molecules for neuroprotection. Mol Biol Rep. 2020;47:3133\u201340. https:\/\/doi.org\/10.1007\/s11033-020-05354-1.","journal-title":"Mol Biol Rep"},{"key":"863_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10571-025-01556-y","volume":"45","author":"W Zhao","year":"2025","unstructured":"Zhao W, Cui H, Liu J, Sun H, Zhang Z, Zhang Z, et al. Herbal Interventions in Parkinson\u2019s Disease: A Systematic Review of Preclinical Studies. Cell Mol Neurobiol. 2025;45:50. https:\/\/doi.org\/10.1007\/s10571-025-01556-y.","journal-title":"Cell Mol Neurobiol"},{"key":"863_CR22","doi-asserted-by":"publisher","first-page":"18534","DOI":"10.1038\/s41598-023-45318-6","volume":"13","author":"R Meenambal","year":"2023","unstructured":"Meenambal R, Kruk T, Gurgul J, Warszy\u0144ski P, Jantas D. Neuroprotective effects of polyacrylic acid (PAA) conjugated cerium oxide against hydrogen peroxide- and 6-OHDA-induced SH-SY5Y cell damage. Sci Rep. 2023;13:18534. https:\/\/doi.org\/10.1038\/s41598-023-45318-6.","journal-title":"Sci Rep"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3390\/ijms25052501","volume":"25","author":"R Meenambal","year":"2024","unstructured":"Meenambal R, Kruk T, Jakubowska K, Gurgul J, Szczepanowicz K, Szcz\u0119ch M, et al. Influence of Eu3\u2009+\u2009Doping on Physiochemical Properties and Neuroprotective Potential of Polyacrylic Acid Functionalized Cerium Oxide Nanoparticles. Int J Mol Sci. 2024;25:2501. https:\/\/doi.org\/10.3390\/ijms25052501.","journal-title":"Int J Mol Sci"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejrad.2006.06.021","volume":"60","author":"MF Bellin","year":"2006","unstructured":"Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60:314\u201323. https:\/\/doi.org\/10.1016\/j.ejrad.2006.06.021.","journal-title":"Eur J Radiol"},{"key":"863_CR25","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1039\/c9sc05937g","volume":"11","author":"CJ Adams","year":"2020","unstructured":"Adams CJ, Meade TJ. Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy. Chem Sci. 2020;11:2524\u201330. https:\/\/doi.org\/10.1039\/c9sc05937g.","journal-title":"Chem Sci"},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00247-021-05098-5","volume":"52","author":"HE Daldrup-Link","year":"2022","unstructured":"Daldrup-Link HE, Theruvath AJ, Rashidi A, Iv M, Majzner RG, Spunt SL, et al. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol. Pediatr Radiol. 2022;52:354\u201366. https:\/\/doi.org\/10.1007\/s00247-021-05098-5.","journal-title":"Pediatr Radiol"},{"key":"863_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/jat.4416","volume":"43","author":"E Akbas","year":"2023","unstructured":"Akbas E, Unal F, Yuzbasioglu D. Cellular toxicities of gadolinium-based contrast agents used in magnetic resonance imaging. J Appl Toxicol. 2023;43:958\u201372. https:\/\/doi.org\/10.1002\/jat.4416.","journal-title":"J Appl Toxicol"},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"104057","DOI":"10.1016\/j.jconhyd.2022.104057","volume":"250","author":"IE Oluwasola","year":"2022","unstructured":"Oluwasola IE, Ahmad AL, Shoparwe NF, Ismail S. Gadolinium based contrast agents (GBCAs): Uniqueness, aquatic toxicity concerns, and prospective remediation. J Contam Hydrol. 2022;250:104057. https:\/\/doi.org\/10.1016\/j.jconhyd.2022.104057.","journal-title":"J Contam Hydrol"},{"key":"863_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3390\/molecules28031165","volume":"28","author":"AL Popov","year":"2023","unstructured":"Popov AL, Savintseva IV, Kozlova TO, Ivanova OS, Zhukov IV, Baranchikov AE, et al. Heavily Gd-Doped Non-Toxic Cerium Oxide Nanoparticles for MRI Labelling of Stem Cells. Molecules. 2023;28:1165. https:\/\/doi.org\/10.3390\/molecules28031165.","journal-title":"Molecules"},{"key":"863_CR30","doi-asserted-by":"publisher","first-page":"15455","DOI":"10.1039\/d4ra01902d","volume":"14","author":"SD Dhruv","year":"2024","unstructured":"Dhruv SD, Kolte J, Solanki P, Deshpande MP, Solanki V, Tailor J, et al. Synthesis, microstructural and optical characterizations of sol-gel grown gadolinium doped cerium oxide ceramics. RSC Adv. 2024;14:15455\u201367. https:\/\/doi.org\/10.1039\/d4ra01902d.","journal-title":"RSC Adv"},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1002\/cpns.88","volume":"91","author":"M Airavaara","year":"2020","unstructured":"Airavaara M, Parkkinen I, Konovalova J, Albert K, Chmielarz P, Domanskyi A. Back and to the Future: From Neurotoxin-Induced to Human Parkinson\u2019s Disease Models. Curr Protoc Neurosci. 2020;91:e88. https:\/\/doi.org\/10.1002\/cpns.88.","journal-title":"Curr Protoc Neurosci"},{"key":"863_CR32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/biom10111530","volume":"10","author":"D Jantas","year":"2020","unstructured":"Jantas D, Chwastek J, Malarz J, Stojakowska A, Laso\u0144 W. Neuroprotective Effects of Methyl Caffeate against Hydrogen Peroxide-Induced Cell Damage: Involvement of Caspase 3 and Cathepsin D Inhibition. Biomolecules. 2020;10:1530. https:\/\/doi.org\/10.3390\/biom10111530.","journal-title":"Biomolecules"},{"key":"863_CR33","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.redox.2020.101678","volume":"36","author":"CT Madreiter-Sokolowski","year":"2020","unstructured":"Madreiter-Sokolowski CT, Thomas C, Ristow M. Interrelation between ROS and Ca2\u2009+\u2009in aging and age-related diseases. Redox Biol. 2020;36:101678. https:\/\/doi.org\/10.1016\/j.redox.2020.101678.","journal-title":"Redox Biol"},{"key":"863_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.bbadis.2013.09.003","volume":"1842","author":"VK Rao","year":"2014","unstructured":"Rao VK, Carlson EA, Yan SS. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim Biophys Acta. 2014;1842:1267\u201372. https:\/\/doi.org\/10.1016\/j.bbadis.2013.09.003.","journal-title":"Biochim Biophys Acta"},{"key":"863_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuropharm.2014.03.019","volume":"83","author":"D Jantas","year":"2014","unstructured":"Jantas D, Greda A, Golda S, Korostynski M, Grygier B, Roman A, et al. Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: the impact of cell differentiation state. Neuropharmacology. 2014;83:36\u201353. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.03.019.","journal-title":"Neuropharmacology"},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/biom14050564","volume":"14","author":"D Jantas","year":"2024","unstructured":"Jantas D, Le\u015bkiewicz M, Regulska M, Procner M, Warszy\u0144ski P, Laso\u0144 W. Protective Effects of Cannabidiol (CBD) against Qxidative Stress, but Not Excitotoxic-Related Neuronal Cell Damage-An In Vitro Study. Biomolecules. 2024;14:564. https:\/\/doi.org\/10.3390\/biom14050564.","journal-title":"Biomolecules"},{"key":"863_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biocel.2017.03.015","volume":"87","author":"J Chwastek","year":"2017","unstructured":"Chwastek J, Jantas D, Laso\u0144 W. The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a \u03b3H2AX\/p-p53\/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D. Int J Biochem Cell Biol. 2017;87:38\u201353. https:\/\/doi.org\/10.1016\/j.biocel.2017.03.015.","journal-title":"Int J Biochem Cell Biol"},{"key":"863_CR38","doi-asserted-by":"publisher","first-page":"103988","DOI":"10.1016\/j.jddst.2022.103988","volume":"78","author":"G Dalei","year":"2022","unstructured":"Dalei G, Das S. Polyacrylic acid-based drug delivery systems: A comprehensive review on the state-of-art. J Drug Deliv Sci Technol. 2022;78:103988. https:\/\/doi.org\/10.1016\/j.jddst.2022.103988.","journal-title":"J Drug Deliv Sci Technol"},{"key":"863_CR39","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/nano13152163","volume":"13","author":"N \u0141opuszy\u0144ska","year":"2023","unstructured":"\u0141opuszy\u0144ska N, W\u0119glarz WP. Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery. Nanomaterials (Basel). 2023;13:2163. https:\/\/doi.org\/10.3390\/nano13152163.","journal-title":"Nanomaterials (Basel)"},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"43607","DOI":"10.1039\/d0ra07507h","volume":"10","author":"M Szcz\u0119ch","year":"2020","unstructured":"Szcz\u0119ch M, Orsi D, \u0141opuszy\u0144ska N, Cristofolini L, Jasi\u0144ski K, W\u0119glarz WP, et al. Magnetically Responsive Polycaprolactone Nanocarriers for Application in the Biomedical Field: Magnetic Hyperthermia, Magnetic Resonance Imaging, and Magnetic Drug Delivery. RSC Adv. 2020;10:43607. https:\/\/doi.org\/10.1039\/d0ra07507h.","journal-title":"RSC Adv"},{"key":"863_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.colsurfa.2017.04.069","volume":"532","author":"K Szczepanowicz","year":"2017","unstructured":"Szczepanowicz K, Piechota P, W\u0119glarz WP, Warszy\u0144ski P. Polyelectrolyte nanocapsules containing iron oxide nanoparticles as MRI detectable drug delivery system. Colloids Surf A. 2017;532:351\u20136. https:\/\/doi.org\/10.1016\/j.colsurfa.2017.04.069.","journal-title":"Colloids Surf A"},{"key":"863_CR42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1063\/1.1731684","volume":"34","author":"N Bloembergen","year":"1961","unstructured":"Bloembergen N, Morgan LO. Proton Relaxation Times in Paramagnetic Solutions. Effects of Electron Spin Relaxation. J Chem Phys. 1961;34:842\u201350. https:\/\/doi.org\/10.1063\/1.1731684.","journal-title":"J Chem Phys"},{"key":"863_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1103\/PhysRev.99.559","volume":"99","author":"I Solomon","year":"1995","unstructured":"Solomon I. Relaxation Processes in a System of Two Spins. Phys Rev. 1995;99:559\u201365. https:\/\/doi.org\/10.1103\/PhysRev.99.559.","journal-title":"Phys Rev"},{"key":"863_CR44","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1103\/PhysRev.104.1542","volume":"104","author":"N Bloembergen","year":"1956","unstructured":"Bloembergen N. Spin Relaxation Processes in a Two-Proton System. Phys Rev. 1956;104:1542\u20137. https:\/\/doi.org\/10.1103\/PhysRev.104.1542.","journal-title":"Phys Rev"},{"issue":"2","key":"863_CR45","doi-asserted-by":"publisher","first-page":"e0149260","DOI":"10.1371\/journal.pone.0149260","volume":"11","author":"A Varga-Szemes","year":"2016","unstructured":"Varga-Szemes A, Kiss P, Rab A, Suranyi P, Lenkey Z, Simor T, et al. In Vitro Longitudinal Relaxivity Profile of Gd(ABE-DTTA), an Investigational Magnetic Resonance Imaging Contrast Agent. PLoS ONE. 2016;11(2):e0149260. https:\/\/doi.org\/10.1371\/journal.pone.0149260.","journal-title":"PLoS ONE"},{"key":"863_CR46","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2147\/IJN.S139326","volume":"12","author":"S Alarifi","year":"2017","unstructured":"Alarifi S, Ali H, Alkahtani S, Alessia MS. Regulation of apoptosis through bcl-2\/bax proteins expression and DNA damage by nano-sized gadolinium oxide. Int J Nanomed. 2017;12:4541\u201351. https:\/\/doi.org\/10.2147\/IJN.S139326.","journal-title":"Int J Nanomed"},{"key":"863_CR47","doi-asserted-by":"publisher","first-page":"15416","DOI":"10.1021\/acsnano.3c08823","volume":"18","author":"X Yin","year":"2024","unstructured":"Yin X, Zhou H, Cao T, Yang X, Meng F, Dai X, et al. Rational Design of Dual-Functionalized Gd@C(82) Nanoparticles to Relieve Neuronal Cytotoxicity in Alzheimer\u2019s Disease via Inhibition of Abeta Aggregation. ACS Nano. 2024;18:15416\u201331. https:\/\/doi.org\/10.1021\/acsnano.3c08823.","journal-title":"ACS Nano"},{"key":"863_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential. Mol Neurodegeneration. 2023;18:83. https:\/\/doi.org\/10.1186\/s13024-023-00676-7.","journal-title":"Mol Neurodegeneration"},{"key":"863_CR49","doi-asserted-by":"publisher","first-page":"e00292","DOI":"10.1016\/j.neurot.2023.10.002","volume":"21","author":"MM Klemmensen","year":"2024","unstructured":"Klemmensen MM, Borrowman SH, Pearce C, Pyles B, Chandra B. Mitochondrial dysfunction in neurodegenerative disorders. Neurotherapeutics. 2024;21:e00292. https:\/\/doi.org\/10.1016\/j.neurot.2023.10.002.","journal-title":"Neurotherapeutics"},{"key":"863_CR50","doi-asserted-by":"publisher","first-page":"7886","DOI":"10.3390\/ijms26167886","volume":"26","author":"D Lewandowski","year":"2025","unstructured":"Lewandowski D, Konieczny M, R\u00f3\u017cycka A, Chrzanowski K, Owecki W, Kalinowski J, et al. Cathepsins in Neurological Diseases. Int J Mol Sci. 2025;26:7886. https:\/\/doi.org\/10.3390\/ijms26167886.","journal-title":"Int J Mol Sci"},{"key":"863_CR51","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41580-024-00757-5","volume":"25","author":"RA Nixon","year":"2024","unstructured":"Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25:926\u201346. https:\/\/doi.org\/10.1038\/s41580-024-00757-5.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"863_CR52","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1186\/s12645-014-0006-6","volume":"5","author":"L Stefan\u010d\u00edkov\u00e1","year":"2014","unstructured":"Stefan\u010d\u00edkov\u00e1 L, Porcel E, Eustache P, Li S, Salado D, Marco S, et al. Cell localisation of gadolinium-based nanoparticles and related radiosensitising efficacy in glioblastoma cells. Cancer Nanotechnol. 2014;5:2014. https:\/\/doi.org\/10.1186\/s12645-014-0006-6.","journal-title":"Cancer Nanotechnol"},{"key":"863_CR53","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1007\/s00216-020-02768-5","volume":"412","author":"ES Tsai","year":"2020","unstructured":"Tsai ES, Joud F, Wiesholler LM, Hirsch T, Hall EAH. Upconversion nanoparticles as intracellular pH messengers. Anal Bioanal Chem. 2020;412:6567\u201381. https:\/\/doi.org\/10.1007\/s00216-020-02768-5.","journal-title":"Anal Bioanal Chem"},{"key":"863_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuro.2008.11.001","volume":"30","author":"YT Cheung","year":"2009","unstructured":"Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, et al. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology. 2009;30:127\u201335. https:\/\/doi.org\/10.1016\/j.neuro.2008.11.001.","journal-title":"Neurotoxicology"},{"key":"863_CR55","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-2010-091363","volume":"20","author":"L Agholme","year":"2010","unstructured":"Agholme L, Lindstr\u00f6m T, K\u00e5gedal K, Marcusson J, Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis. 2010;20:1069\u201382. https:\/\/doi.org\/10.3233\/JAD-2010-091363.","journal-title":"J Alzheimers Dis"},{"key":"863_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.31083\/j.jin2201020","volume":"22","author":"OC Ioghen","year":"2023","unstructured":"Ioghen OC, Ceafalan LC, Popescu BO. SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research-Old Practice for New Trends. J Integr Neurosci. 2023;22:20. https:\/\/doi.org\/10.31083\/j.jin2201020.","journal-title":"J Integr Neurosci"},{"key":"863_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10571-025-01544-2","volume":"45","author":"S Yaribash","year":"2025","unstructured":"Yaribash S, Mohammadi K, Sani MA. Alpha-Synuclein Pathophysiology in Neurodegenerative Disorders: A Review Focusing on Molecular Mechanisms and Treatment Advances in Parkinson\u2019s Disease. Cell Mol Neurobiol. 2025;45:30. https:\/\/doi.org\/10.1007\/s10571-025-01544-2.","journal-title":"Cell Mol Neurobiol"},{"key":"863_CR58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s43440-020-00120-3","volume":"72","author":"P Chmielarz","year":"2020","unstructured":"Chmielarz P, Saarma M. Neurotrophic factors for disease-modifying treatments of Parkinson\u2019s disease: gaps between basic science and clinical studies. Pharmacol Rep. 2020;72:1195\u2013217. https:\/\/doi.org\/10.1007\/s43440-020-00120-3.","journal-title":"Pharmacol Rep"},{"issue":"Pt B","key":"863_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","volume":"109","author":"EM Rocha","year":"2018","unstructured":"Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease. Neurobiol Dis. 2018;109(Pt B):249\u201357. https:\/\/doi.org\/10.1016\/j.nbd.2017.04.004.","journal-title":"Neurobiol Dis"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00863-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:32Z","timestamp":1785856892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00863-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00863-5","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}